Deal announcement

goetzpartners advised tesa SE

20. September 2022

goetzpartners advised tesa SE on the sale of tesa Labtec GmbH

goetzpartners advised tesa SE on the sale of tesa Labtec GmbH, a specialty pharmaceutical drug delivery contract development and manufacturing organization ("CDMO").

goetzpartners acted as exclusive M&A advisor to tesa. This transaction is goetzpartners' fifth transaction in the CDMO sector within only a few months.

About AdhexPharma
AdhexPharma is a pharmaceutical company specializing in the development and manufacturing of transdermal patches, oral thin films and hard-to-make dosage forms. As such AdhexPharma provides its customers with an industrial, technology expertise and know-how in the formulation, development, and commercial production of such systems. It is cGMP compliant, for both Europe and US and can handle both highly potent APIs and narcotics. Founded in 2007 for the purpose of acquiring the transdermal patch unit of Solvay in France, AdhexPharma currently manufactures five approved products representing more than 80 million units per year. AdhexPharma is headquartered in Paris and operates industrial activities in facilities located south of Dijon, France and south of Munich, Germany. AdhexPharma is part of Burgundy Ventures, an independent French industrial holding, along with its sister company Adhex.

Transaction Team

Ulrich Kinzel
Managing Director

Fabio Riva
Associate Director

David Dörsam

Simon Fischer